Capreomycin sulfate compatibility reconstitution and stability

Revision as of 21:59, 24 December 2013 by Chetan Lokhande (talk | contribs) (Created page with "__NOTOC__ {{Capreomycin sulfate}} {{CMG}} ; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Capreomycin Sulfate
CAPASTAT SULFATE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]


[1]

References

  1. ↑ "CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN]". Text " accessdate " ignored (help)

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Capreomycin_sulfate_compatibility_reconstitution_and_stability&oldid=919527"